文献速递胸部肿瘤

早期非小细胞肺癌立体定向放疗生物有效剂量与生存关系

Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients With Early-Stage NSCLC.
PubMed 文献 · J Thorac Oncol · 2019-08-31

该回顾性研究利用美国国家癌症数据库分析2004至2014年临床I期NSCLC接受SBRT的患者,按BED10分为低剂量组(100-129 Gy)和高剂量组(≥130 Gy),匹配分析显示高BED10组5年OS更优(34% vs 26%,p=0.039),低BED10与更差生存独立相关(HR=1.046,95%CI 1.004-1.090,p=0.032)。

要点

  • 高BED10(≥130 Gy)SBRT与早期NSCLC更优的5年OS相关。
  • 低BED10(100-129 Gy)使用比例上升,但与更差生存独立相关。
  • 需进一步研究剂量-反应关系及高BED10方案的毒性。

核心结论

  • 低BED10 SBRT治疗I期NSCLC越来越常见,但BED10≥130 Gy的方案可能带来额外生存获益。

研究设计与样本

  • 回顾性研究,使用美国国家癌症数据库纳入2004至2014年临床I期(cT1-2aN0M0)NSCLC接受SBRT的患者。
  • 共25,039例患者分为低BED组(100-129 Gy,n=14,756,59%)和高BED组(≥130 Gy,n=10,283,41%),基于患者和肿瘤特征进行1:1匹配分析,匹配后20,542例。
  • 未评估肿瘤中心位置。

主要发现

  • 高BED向低BED SBRT方案使用的转变与关键文献发表相关。
  • 匹配队列中,低BED组5年OS率为26%,高BED组为34%(p=0.039)。
  • 多因素分析显示,接受低BED与显著更差的生存相关(HR=1.046,95%CI 1.004-1.090,p=0.032)。

临床怎么用

  • 对于早期NSCLC的SBRT,考虑使用BED10≥130 Gy的方案可能改善生存。
  • 需权衡高BED10方案的毒性,并进一步研究剂量-反应关系。

局限性

  • 回顾性研究设计。
  • 未评估肿瘤中心位置。
  • 需要额外研究评估现代高BED SBRT的剂量-反应关系和毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Stereotactic body radiotherapy (SBRT) results in excellent local control of stage I NSCLC. Radiobiology models predict greater tumor response when higher biologically effective doses (BED10) are given. Prior studies support a BED10 greater than or equal to 100 Gy with SBRT; however, data are limited comparing outcomes after various SBRT regimens. We therefore sought to evaluate national trends and the effect of using "low" versus "high" BED10 SBRT courses on overall survival (OS). METHODS: This retrospective study used the National Cancer Data Base to identify patients diagnosed with clinical stage I (cT1-2aN0M0) NSCLC from 2004 to 2014 treated with SBRT. Patients were categorized into LowBED (100-129 Gy) or HighBED (≥130 Gy) groups. A 1:1 matched analysis based on patient and tumor characteristics was used to compare OS by BED10 group. Tumor centrality was not assessed. RESULTS: O 25,039 patients treated with LowBED (n = 14,756; 59%) or HighBED (n = 10,283; 41%) SBRT, 20,542 were matched. Shifts in HighBED to LowBED SBRT regimen use correlated with key publications in the literature. In the matched cohort, 5-year OS rates were 26% for LowBED and 34% for HighBED groups (p = 0.039). On multivariate analysis, receipt of LowBED was associated with significantly worse survival (hazard ratio = 1.046, 95% confidence interval: 1.004-1.090, p = 0.032). CONCLUSIONS: LowBED SBRT for treating stage I NSCLC is becoming more common. However, our findings suggest SBRT regimens with BED10 greater than or equal to 130 Gy may confer an additional survival benefit. Additional studies are required to evaluate the dose-response relationship and toxicities associated with modern HighBED SBRT.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Moreno AC, Fellman B, Hobbs BP, et al. Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients With Early-Stage NSCLC. J Thorac Oncol. 2019. PMID: 31479748. doi:10.1016/j.jtho.2019.08.2505

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。